DOCSLIB.ORG

Semaphorin 3A—Glycosaminoglycans Interaction As Therapeutic Target for Axonal Regeneration

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

pharmaceuticals Article Semaphorin 3A—Glycosaminoglycans Interaction as Therapeutic Target for Axonal Regeneration Yolanda Pérez 1,* , Roman Bonet 2, Miriam Corredor 2, Cecilia Domingo 2, Alejandra Moure 2, Àngel Messeguer 2, Jordi Bujons 2 and Ignacio Alfonso 2,* 1 NMR Facility, Institute for Advanced Chemistry of Catalonia (IQAC-CSIC), Jordi Girona 18-26, 08034 Barcelona, Spain 2 Department of Biological Chemistry, Institute for Advanced Chemistry of Catalonia (IQAC-CSIC), Jordi Girona 18-26, 08034 Barcelona, Spain; [email protected] (R.B.); [email protected] (M.C.); [email protected] (C.D.); [email protected] (A.M.); [email protected] (À.M.); [email protected] (J.B.) * Correspondence: [email protected] (Y.P.); [email protected] (I.A.) Abstract: Semaphorin 3A (Sema3A) is a cell-secreted protein that participates in the axonal guidance pathways. Sema3A acts as a canonical repulsive axon guidance molecule, inhibiting CNS regenerative axonal growth and propagation. Therefore, interfering with Sema3A signaling is proposed as a therapeutic target for achieving functional recovery after CNS injuries. It has been shown that Sema3A adheres to the proteoglycan component of the extracellular matrix (ECM) and selectively binds to heparin and chondroitin sulfate-E (CS-E) glycosaminoglycans (GAGs). We hypothesize that Citation: Pérez, Y.; Bonet, R.; the biologically relevant interaction between Sema3A and GAGs takes place at Sema3A C-terminal Corredor, M.; Domingo, C.; polybasic region (SCT). The aims of this study were to characterize the interaction of the whole Moure, A.; Messeguer, À.; Bujons, J.; Sema3A C-terminal polybasic region (Sema3A 725–771) with GAGs and to investigate the disruption Alfonso, I. Semaphorin of this interaction by small molecules. Recombinant Sema3A basic domain was produced and we 3A—Glycosaminoglycans Interaction as Therapeutic Target for Axonal used a combination of biophysical techniques (NMR, SPR, and heparin affinity chromatography) Regeneration. Pharmaceuticals 2021, to gain insight into the interaction of the Sema3A C-terminal domain with GAGs. The results 14, 906. https://doi.org/10.3390/ demonstrate that SCT is an intrinsically disordered region, which confirms that SCT binds to GAGs ph14090906 and helps to identify the specific residues involved in the interaction. NMR studies, supported by molecular dynamics simulations, show that a new peptoid molecule (CSIC02) may disrupt the Academic Editors: interaction between SCT and heparin. Our structural study paves the way toward the design of new Jesus Jimenez-Barbero and molecules targeting these protein–GAG interactions with potential therapeutic applications. Óscar Millet Keywords: semaphorin 3A; NMR; glycosaminoglycan–protein interaction; peptoids Received: 4 August 2021 Accepted: 1 September 2021 Published: 7 September 2021 1. Introduction Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in The extracellular matrix (ECM) is a dynamic three-dimensional network of macro- published maps and institutional affil- molecules that offers structural support for the cells and tissues and provides a microen- iations. vironment that regulates neural cell development and activity [1]. One of the building blocks of these networks are the proteoglycans (PGs). Proteoglycans are constituted by core proteins and one or several attached glycosaminoglycan (GAG) chains. PGs are present in ECM and on the cell membrane surface. GAGs play numerous biological roles mediated by the interaction with a variety of proteins [2–5]. GAG–protein interactions Copyright: © 2021 by the authors. participate in a variety of human diseases, including cardiovascular diseases, infections, Licensee MDPI, Basel, Switzerland. This article is an open access article neurodegenerative processes, and tumors [6,7]. Numerous experiments have established distributed under the terms and that the protein Semaphorin 3A (Sema3A) co-localizes with both cell surface and ECM conditions of the Creative Commons chondroitin/heparan sulfate proteoglycans (CSPGs/HSPGs) [8–10]. Sema3A interacts with Attribution (CC BY) license (https:// CSPGs in perineuronal nets (PNN, one form of ECM in the central nervous system (CNS)), creativecommons.org/licenses/by/ depending, among other features, on the sulfation pattern [10–13]. Early data showed 4.0/). that heparin enhances Sema3A binding to neuropilin-1-expressing cells and potentiates Pharmaceuticals 2021, 14, 906. https://doi.org/10.3390/ph14090906 https://www.mdpi.com/journal/pharmaceuticals Pharmaceuticals 2021, 14, x FOR PEER REVIEW 2 of 24 Pharmaceuticals 2021, 14, 906 2 of 24 heparin enhances Sema3A binding to neuropilin-1-expressing cells and potentiates its growthits growth cone cone collapsing collapsing activity activity [8]. [Sema3A8]. Sema3A modulates modulates PNN PNN plasticity plasticity and and the the coexist- coexis- encetence of ofboth both Sema3A Sema3A and and chondroitin chondroitin sulfate sulfate (CS) (CS) on on the the neuronal neuronal surface surface gives gives stronger stronger plasticityplasticity restriction restriction in in PNN PNN [13] [13. ].These These studies studies support support the the contribution contribution of of CSPGs CSPGs to to the the Sema3ASema3A-Nrp-Plxn-Nrp-Plxn (Nr (Nrpp = =N Neuropilin;europilin; Plx Plxnn = =Plexin) Plexin) signaling signaling complex complex (Figure (Figure 1)1.). FigureFigure 1. 1.SchematicSchematic illustration illustration of of the the mechanism mechanism of of action action proposed proposed for for our our small small cationic cationic peptidomimetics peptidomimetics through through the the directdirect inhibition inhibition of of a abiologically biologically relevant relevant Sema3A Sema3A polybasic polybasic C C-terminal-terminal region region (SCT) (SCT)–GAG–GAG interaction. interaction. Sema3A Sema3A form formss ternaryternary complexes complexes with with its its receptor receptor proteins proteins (Nrps (Nrps-Plxs;-Plxs; Nrp1 Nrp1-PlxnA2-PlxnA2 is isas as example example of of interaction interaction partners). partners). The The figure figure shows the proposed inhibition mechanism of the Sema3A pathway by interfering the colocalization of secreted Sema3A shows the proposed inhibition mechanism of the Sema3A pathway by interfering the colocalization of secreted Sema3A with its receptor proteins (Nrp1-PlxnA2) due to CSIC02 binding to GAG sites. Long black lines represent the protein part with its receptor proteins (Nrp1-PlxnA2) due to CSIC02 binding to GAG sites. Long black lines represent the protein part of proteoglycans (PGs), red lines represent negatively charged sugar (GAG) chains. Sema3A/Nrp1/PllnxA2 domains: PSI (plexinof proteoglycans-semaphorin (PGs),-integrin), red Ig lines (immu representnoglobulin), negatively SCT (basic), charged IPT sugar (transcription (GAG) chains. factors), Sema3A/Nrp1/PllnxA2 GAP (GTPase-Activating domains: Pro- tein),PSI (plexin-semaphorin-integrin),a1/a2 (CUB), b1/b2 (FV/VIII), and Ig (immunoglobulin), c (MAM). SCT (basic), IPT (transcription factors), GAP (GTPase-Activating Protein), a1/a2 (CUB), b1/b2 (FV/VIII), and c (MAM). Sema3A is a member of the class-3 secreted Semaphorins. Semaphorins are classified on the Sema3Abasis of the isa specific member structure of the class-3 of their secreted C-terminal Semaphorins. domains [14] Semaphorins. Semaphorin are class classi--3 arefied secreted on the proteins basis of thecontaining specific a structure C-terminal of theirpolybasic C-terminal domain, domains an Ig-like [14 ].C2 Semaphorin-type (im- munoglobulinclass-3 are secreted-like) domain, proteins a containing PSI domain a, C-terminal and a Sema polybasic domain.domain, The Semaphorins an Ig-like C2-typerecep- (immunoglobulin-like) domain, a PSI domain, and a Sema domain. The Semaphorins re- tors, neuropilins and plexins, are expressed in a variety of cell types, including neurons, ceptors, neuropilins and plexins, are expressed in a variety of cell types, including neurons, endothelial cells, and cancer cells. Sema3A was initially characterized as an axon guidance endothelial cells, and cancer cells. Sema3A was initially characterized as an axon guidance molecule that takes part in regulating the process by which axon growth cones are di- molecule that takes part in regulating the process by which axon growth cones are directed rected to their appropriate targets during the nervous system growth. In the adult CNS, to their appropriate targets during the nervous system growth. In the adult CNS, Sema3A Sema3A acts as a canonical repulsive axon guidance molecule, inhibiting CNS regenera- acts as a canonical repulsive axon guidance molecule, inhibiting CNS regenerative axonal tive axonal growth and sprouting [12]. In addition, Sema3A can also function as chemo- growth and sprouting [12]. In addition, Sema3A can also function as chemo-attractive attractive agent, stimulating the growth of apical dendrites [15]. Moreover, class-3 Sema- agent, stimulating the growth of apical dendrites [15]. Moreover, class-3 Semaphorins phorins also play a role in many processes outside the nervous system, as tumor progres- also play a role in many processes outside the nervous system, as tumor progression or sion or suppression [16,17] or in the immune system [18,19] and are attracting much at- suppression [16,17] or in the immune system [18,19] and are attracting much attention as tention as potential therapeutic targets [20,21]. potential therapeutic targets [20,21]. PNNsPNNs are are
Recommended publications
  • Prioritization and Evaluation of Depression Candidate Genes by Combining Multidimensional Data Resources

    Prioritization and Evaluation of Depression Candidate Genes by Combining Multidimensional Data Resources

    Prioritization and Evaluation of Depression Candidate Genes by Combining Multidimensional Data Resources Chung-Feng Kao1, Yu-Sheng Fang2, Zhongming Zhao3, Po-Hsiu Kuo1,2,4* 1 Department of Public Health and Institute of Epidemiology and Preventive Medicine, College of Public Health, National Taiwan University, Taipei, Taiwan, 2 Institute of Clinical Medicine, School of Medicine, National Cheng-Kung University, Tainan, Taiwan, 3 Departments of Biomedical Informatics and Psychiatry, Vanderbilt University School of Medicine, Nashville, Tennessee, United States of America, 4 Research Center for Genes, Environment and Human Health, National Taiwan University, Taipei, Taiwan Abstract Background: Large scale and individual genetic studies have suggested numerous susceptible genes for depression in the past decade without conclusive results. There is a strong need to review and integrate multi-dimensional data for follow up validation. The present study aimed to apply prioritization procedures to build-up an evidence-based candidate genes dataset for depression. Methods: Depression candidate genes were collected in human and animal studies across various data resources. Each gene was scored according to its magnitude of evidence related to depression and was multiplied by a source-specific weight to form a combined score measure. All genes were evaluated through a prioritization system to obtain an optimal weight matrix to rank their relative importance with depression using the combined scores. The resulting candidate gene list for depression (DEPgenes) was further evaluated by a genome-wide association (GWA) dataset and microarray gene expression in human tissues. Results: A total of 5,055 candidate genes (4,850 genes from human and 387 genes from animal studies with 182 being overlapped) were included from seven data sources.
  • Supplemental Table 1. Complete Gene Lists and GO Terms from Figure 3C

    Supplemental Table 1. Complete Gene Lists and GO Terms from Figure 3C

    Supplemental Table 1. Complete gene lists and GO terms from Figure 3C. Path 1 Genes: RP11-34P13.15, RP4-758J18.10, VWA1, CHD5, AZIN2, FOXO6, RP11-403I13.8, ARHGAP30, RGS4, LRRN2, RASSF5, SERTAD4, GJC2, RHOU, REEP1, FOXI3, SH3RF3, COL4A4, ZDHHC23, FGFR3, PPP2R2C, CTD-2031P19.4, RNF182, GRM4, PRR15, DGKI, CHMP4C, CALB1, SPAG1, KLF4, ENG, RET, GDF10, ADAMTS14, SPOCK2, MBL1P, ADAM8, LRP4-AS1, CARNS1, DGAT2, CRYAB, AP000783.1, OPCML, PLEKHG6, GDF3, EMP1, RASSF9, FAM101A, STON2, GREM1, ACTC1, CORO2B, FURIN, WFIKKN1, BAIAP3, TMC5, HS3ST4, ZFHX3, NLRP1, RASD1, CACNG4, EMILIN2, L3MBTL4, KLHL14, HMSD, RP11-849I19.1, SALL3, GADD45B, KANK3, CTC- 526N19.1, ZNF888, MMP9, BMP7, PIK3IP1, MCHR1, SYTL5, CAMK2N1, PINK1, ID3, PTPRU, MANEAL, MCOLN3, LRRC8C, NTNG1, KCNC4, RP11, 430C7.5, C1orf95, ID2-AS1, ID2, GDF7, KCNG3, RGPD8, PSD4, CCDC74B, BMPR2, KAT2B, LINC00693, ZNF654, FILIP1L, SH3TC1, CPEB2, NPFFR2, TRPC3, RP11-752L20.3, FAM198B, TLL1, CDH9, PDZD2, CHSY3, GALNT10, FOXQ1, ATXN1, ID4, COL11A2, CNR1, GTF2IP4, FZD1, PAX5, RP11-35N6.1, UNC5B, NKX1-2, FAM196A, EBF3, PRRG4, LRP4, SYT7, PLBD1, GRASP, ALX1, HIP1R, LPAR6, SLITRK6, C16orf89, RP11-491F9.1, MMP2, B3GNT9, NXPH3, TNRC6C-AS1, LDLRAD4, NOL4, SMAD7, HCN2, PDE4A, KANK2, SAMD1, EXOC3L2, IL11, EMILIN3, KCNB1, DOK5, EEF1A2, A4GALT, ADGRG2, ELF4, ABCD1 Term Count % PValue Genes regulation of pathway-restricted GDF3, SMAD7, GDF7, BMPR2, GDF10, GREM1, BMP7, LDLRAD4, SMAD protein phosphorylation 9 6.34 1.31E-08 ENG pathway-restricted SMAD protein GDF3, SMAD7, GDF7, BMPR2, GDF10, GREM1, BMP7, LDLRAD4, phosphorylation
  • The Role of Semaphorins and Their Receptors in Vascular Development and Cancer

    The Role of Semaphorins and Their Receptors in Vascular Development and Cancer

    EXPERIMENTAL CELL RESEARCH ] ( ]]]]) ]]]– ]]] Available online at www.sciencedirect.com journal homepage: www.elsevier.com/locate/yexcr Review Article The role of semaphorins and their receptors in vascular development and cancer Chenghua Gua,n, Enrico Giraudob,nn aDepartment of Neurobiology, Harvard Medical School, 220 Longwood Ave, Boston, MA 02115, USA bInstitute for Cancer Research at Candiolo (IRC@C), and Department of Science and Drug Technology, University of Torino, Str. Prov. 142 Km.3,95 10060 Candiolo, Turin, Italy article information abstract Article Chronology: Semaphorins (Semas) are a large family of traditional axon guidance molecules. Through Received 1 February 2013 interactions with their receptors, Plexins and Neuropilins, Semas play critical roles in a Accepted 6 February 2013 continuously growing list of diverse biological systems. In this review, we focus on their function in regulating vascular development. In addition, over the past few years a number of Keywords: findings have shown the crucial role that Semas and their receptors play in the regulation of Semaphorin cancer progression and tumor angiogenesis. In particular, Semas control tumor progression by Plexin directly influencing the behavior of cancer cells or, indirectly, by modulating angiogenesis and Neuropilin the function of other cell types in the tumor microenvironment (i.e., inflammatory cells and Angiogenesis fibroblasts). Some Semas can activate or inhibit tumor progression and angiogenesis, while Cancer others may have the opposite effect depending on specific post-translational modifications. Here Tumor we will also discuss the diverse biological effects of Semas and their receptor complexes on Development cancer progression as well as their impact on the tumor microenvironment. & Vasculature 2013 Elsevier Inc.
  • Plexin A4 (PLXNA4) (NM 181775) Human Recombinant Protein – TP761981 | Origene

    Plexin A4 (PLXNA4) (NM 181775) Human Recombinant Protein – TP761981 | Origene

    OriGene Technologies, Inc. 9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 [email protected] EU: [email protected] CN: [email protected] Product datasheet for TP761981 Plexin A4 (PLXNA4) (NM_181775) Human Recombinant Protein Product data: Product Type: Recombinant Proteins Description: Purified recombinant protein of Human plexin A4 (PLXNA4), transcript variant 2,full length, with N-terminal GST and C-terminal His tag, expressed in E. coli, 50ug Species: Human Expression Host: E. coli Tag: N-GST and C-His Predicted MW: 86 kDa Concentration: >50 ug/mL as determined by microplate BCA method Purity: > 80% as determined by SDS-PAGE and Coomassie blue staining Buffer: 25mM Tris, pH8.0, 150 mM NaCl, 10% glycerol,1% Sarkosyl. Storage: Store at -80°C. Stability: Stable for 12 months from the date of receipt of the product under proper storage and handling conditions. Avoid repeated freeze-thaw cycles. RefSeq: NP_861440 Locus ID: 91584 UniProt ID: Q9HCM2 RefSeq Size: 2020 Cytogenetics: 7q32.3 RefSeq ORF: 1566 Synonyms: FAYV2820; PLEXA4; PLXNA4A; PLXNA4B; PRO34003 Summary: Coreceptor for SEMA3A. Necessary for signaling by class 3 semaphorins and subsequent remodeling of the cytoskeleton. Plays a role in axon guidance in the developing nervous system. Class 3 semaphorins bind to a complex composed of a neuropilin and a plexin. The plexin modulates the affinity of the complex for specific semaphorins, and its cytoplasmic domain is required for the activation of down-stream signaling events in the cytoplasm (By similarity).[UniProtKB/Swiss-Prot Function] Protein Families: Druggable Genome This product is to be used for laboratory only.
  • Expression of a Mirna Targeting Mutated SOD1 in Astrocytes Induces Motoneuron Plasticity and Improves Neuromuscular Function in ALS Mice

    Expression of a Mirna Targeting Mutated SOD1 in Astrocytes Induces Motoneuron Plasticity and Improves Neuromuscular Function in ALS Mice

    bioRxiv preprint doi: https://doi.org/10.1101/2021.01.08.425706; this version posted January 9, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. Expression of a miRNA targeting mutated SOD1 in astrocytes induces motoneuron plasticity and improves neuromuscular function in ALS mice Rochat C.1, Bernard-Marissal N.1,6, Pradervand S.3, Perrin F.E.4, Raoul C.5, Aebischer P.1, Schneider B.L.1,2* 1 Brain Mind Institute, Ecole Polytechnique Fédérale de Lausanne (EPFL), 1015 Lausanne, Switzerland 2 Bertarelli Platform for Gene Therapy, Ecole Polytechnique Fédérale de Lausanne (EPFL), Geneva, Switzerland 3 Genomic Technologies Facility, University of Lausanne, Lausanne, Switzerland. 4 INSERM U1198, University of Montpellier, EPHE, Place Eugène Bataillon CC105, F-34095, Montpellier, France 5 The Neuroscience Institute of Montpellier, Inserm UMR1051, Univ Montpellier, Saint Eloi Hospital, Montpellier, France 6 Aix Marseille Univ, INSERM, MMG, Marseille, France *Correspondence should be addressed to B.L.S. ([email protected]) Short title: miRNA gene therapy targeting astrocytes in ALS Study was performed in Lausanne, Switzerland Current address of corresponding author: Bernard Schneider EPFL SV PTECH PTBTG Ch. des Mines 9 CH-1202 Genève Switzerland Email: [email protected] Tel: +41 21 693 95 05 bioRxiv preprint doi: https://doi.org/10.1101/2021.01.08.425706; this version posted January 9, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
  • The Expression of Key Guidance Genes at a Forebrain Axon Turning Point Is Maintained by Distinct Fgfr Isoforms but a Common Downstream Signal Transduction Mechanism

    The Expression of Key Guidance Genes at a Forebrain Axon Turning Point Is Maintained by Distinct Fgfr Isoforms but a Common Downstream Signal Transduction Mechanism

    New Research Development The Expression of Key Guidance Genes at a Forebrain Axon Turning Point Is Maintained by Distinct Fgfr Isoforms but a Common Downstream Signal Transduction Mechanism Jung-Lynn Jonathan Yang, Gabriel E. Bertolesi, Stephanie Dueck, Carrie L. Hehr, and Sarah McFarlane https://doi.org/10.1523/ENEURO.0086-19.2019 Department of Cell Biology and Anatomy, Hotchkiss Brain Institute, Alberta Children’s Hospital Research Institute, Cumming School of Medicine, University of Calgary, Calgary, Alberta T2N 4N1, Canada Abstract During development the axons of neurons grow toward and locate their synaptic partners to form functional neural circuits. Axons do so by reading a map of guidance cues expressed by surrounding tissues. Guidance cues are expressed at a precise space and time, but how guidance cue expression is regulated, and in a coordinated manner, is poorly understood. Semaphorins (Semas) and Slits are families of molecular ligands that guide axons. We showed previously that fibroblast growth factor (Fgf) signaling maintains sema3a and slit1 forebrain expres- sion in Xenopus laevis, and these two repellents cooperate to guide retinal ganglion cell (RGC) axons away from the mid-diencephalon and on towards the optic tectum. Here, we investigate whether there are common features of the regulatory pathways that control the expression of these two guidance cues at this single axon guidance decision point. We isolated the sema3a proximal promoter and confirmed its responsiveness to Fgf signaling. Through misexpression of truncated Fgf receptors (Fgfrs), we found that sema3a forebrain expression is dependent on Fgfr2-4 but not Fgfr1. This is in contrast to slit1, whose expression we showed previously depends on Fgfr1 but not Fgfr2-4.
  • Whole Genome Sequencing of Familial Non-Medullary Thyroid Cancer Identifies Germline Alterations in MAPK/ERK and PI3K/AKT Signaling Pathways

    Whole Genome Sequencing of Familial Non-Medullary Thyroid Cancer Identifies Germline Alterations in MAPK/ERK and PI3K/AKT Signaling Pathways

    biomolecules Article Whole Genome Sequencing of Familial Non-Medullary Thyroid Cancer Identifies Germline Alterations in MAPK/ERK and PI3K/AKT Signaling Pathways Aayushi Srivastava 1,2,3,4 , Abhishek Kumar 1,5,6 , Sara Giangiobbe 1, Elena Bonora 7, Kari Hemminki 1, Asta Försti 1,2,3 and Obul Reddy Bandapalli 1,2,3,* 1 Division of Molecular Genetic Epidemiology, German Cancer Research Center (DKFZ), D-69120 Heidelberg, Germany; [email protected] (A.S.); [email protected] (A.K.); [email protected] (S.G.); [email protected] (K.H.); [email protected] (A.F.) 2 Hopp Children’s Cancer Center (KiTZ), D-69120 Heidelberg, Germany 3 Division of Pediatric Neurooncology, German Cancer Research Center (DKFZ), German Cancer Consortium (DKTK), D-69120 Heidelberg, Germany 4 Medical Faculty, Heidelberg University, D-69120 Heidelberg, Germany 5 Institute of Bioinformatics, International Technology Park, Bangalore 560066, India 6 Manipal Academy of Higher Education (MAHE), Manipal, Karnataka 576104, India 7 S.Orsola-Malphigi Hospital, Unit of Medical Genetics, 40138 Bologna, Italy; [email protected] * Correspondence: [email protected]; Tel.: +49-6221-42-1709 Received: 29 August 2019; Accepted: 10 October 2019; Published: 13 October 2019 Abstract: Evidence of familial inheritance in non-medullary thyroid cancer (NMTC) has accumulated over the last few decades. However, known variants account for a very small percentage of the genetic burden. Here, we focused on the identification of common pathways and networks enriched in NMTC families to better understand its pathogenesis with the final aim of identifying one novel high/moderate-penetrance germline predisposition variant segregating with the disease in each studied family.
  • Case–Control Association Study of 59 Candidate Genes Reveals the DRD2

    Case–Control Association Study of 59 Candidate Genes Reveals the DRD2

    Journal of Human Genetics (2009) 54, 98–107 & 2009 The Japan Society of Human Genetics All rights reserved 1434-5161/09 $32.00 www.nature.com/jhg ORIGINAL ARTICLE Case–control association study of 59 candidate genes reveals the DRD2 SNP rs6277 (C957T) as the only susceptibility factor for schizophrenia in the Bulgarian population Elitza T Betcheva1, Taisei Mushiroda2, Atsushi Takahashi3, Michiaki Kubo4, Sena K Karachanak5, Irina T Zaharieva5, Radoslava V Vazharova5, Ivanka I Dimova5, Vihra K Milanova6, Todor Tolev7, George Kirov8, Michael J Owen8, Michael C O’Donovan8, Naoyuki Kamatani3, Yusuke Nakamura1,9 and Draga I Toncheva5 The development of molecular psychiatry in the last few decades identified a number of candidate genes that could be associated with schizophrenia. A great number of studies often result with controversial and non-conclusive outputs. However, it was determined that each of the implicated candidates would independently have a minor effect on the susceptibility to that disease. Herein we report results from our replication study for association using 255 Bulgarian patients with schizophrenia and schizoaffective disorder and 556 Bulgarian healthy controls. We have selected from the literatures 202 single nucleotide polymorphisms (SNPs) in 59 candidate genes, which previously were implicated in disease susceptibility, and we have genotyped them. Of the 183 SNPs successfully genotyped, only 1 SNP, rs6277 (C957T) in the DRD2 gene (P¼0.0010, odds ratio¼1.76), was considered to be significantly associated with schizophrenia after the replication study using independent sample sets. Our findings support one of the most widely considered hypotheses for schizophrenia etiology, the dopaminergic hypothesis.
  • Whole Exome Sequencing Reveals NOTCH1 Mutations in Anaplastic Large Cell Lymphoma and Points to Notch Both As a Key Pathway and a Potential Therapeutic Target

    Whole Exome Sequencing Reveals NOTCH1 Mutations in Anaplastic Large Cell Lymphoma and Points to Notch Both As a Key Pathway and a Potential Therapeutic Target

    Non-Hodgkin Lymphoma SUPPLEMENTARY APPENDIX Whole exome sequencing reveals NOTCH1 mutations in anaplastic large cell lymphoma and points to Notch both as a key pathway and a potential therapeutic target Hugo Larose, 1,2 Nina Prokoph, 1,2 Jamie D. Matthews, 1 Michaela Schlederer, 3 Sandra Högler, 4 Ali F. Alsulami, 5 Stephen P. Ducray, 1,2 Edem Nuglozeh, 6 Mohammad Feroze Fazaludeen, 7 Ahmed Elmouna, 6 Monica Ceccon, 2,8 Luca Mologni, 2,8 Carlo Gambacorti-Passerini, 2,8 Gerald Hoefler, 9 Cosimo Lobello, 2,10 Sarka Pospisilova, 2,10,11 Andrea Janikova, 2,11 Wilhelm Woessmann, 2,12 Christine Damm-Welk, 2,12 Martin Zimmermann, 13 Alina Fedorova, 14 Andrea Malone, 15 Owen Smith, 15 Mariusz Wasik, 2,16 Giorgio Inghirami, 17 Laurence Lamant, 18 Tom L. Blundell, 5 Wolfram Klapper, 19 Olaf Merkel, 2,3 G. A. Amos Burke, 20 Shahid Mian, 6 Ibraheem Ashankyty, 21 Lukas Kenner 2,3,22 and Suzanne D. Turner 1,2,10 1Department of Pathology, University of Cambridge, Cambridge, UK; 2European Research Initiative for ALK Related Malignancies (ERIA; www.ERIALCL.net ); 3Department of Pathology, Medical University of Vienna, Vienna, Austria; 4Unit of Laboratory Animal Pathology, Uni - versity of Veterinary Medicine Vienna, Vienna, Austria; 5Department of Biochemistry, University of Cambridge, Tennis Court Road, Cam - bridge, UK; 6Molecular Diagnostics and Personalised Therapeutics Unit, Colleges of Medicine and Applied Medical Sciences, University of Ha’il, Ha’il, Saudi Arabia; 7Neuroinflammation Research Group, Department of Neurobiology, A.I Virtanen Institute
  • Molecular Genetics of Schizophrenia and Related Intermediate

    Molecular Genetics of Schizophrenia and Related Intermediate

    Juho Wedenoja c R Molecular Genetics of e S Schizophrenia and Related Rea h Intermediate Phenotypes in a Founder Population Phenotypes in a Founder Population Founder a in Phenotypes Intermediate Related and Schizophrenia of Genetics Molecular 28 2010 28 Juho Wedenoja Molecular Genetics of Schizophrenia and Related Intermediate Phenotypes in a Founder Population ACADEMIC DISSERTATION To be presented, with the permission of the Faculty of Medicine, University of Helsinki, for public examination in the Small Hall, University of Helsinki Main Building, on 5 February 2010, at 12 noon. National Institute for Health and Welfare, Helsinki, Finland and Institute for Molecular Medicine Finland FIMM, Helsinki, Finland and Department of Medical Genetics, University of Helsinki, Helsinki, Finland RESEARCH 28 Helsinki 2010 Helsinki University Biomedical Dissertations No 131 ISSN 1457-8433 Publications of the National Institute for Health and Welfare Research 28 © Juho Wedenoja & National Institute for Health and Welfare 2010 ISBN 978-952-245-219-1 (print) ISSN 1798-0054 (print) ISBN 978-952-245-220-7 (pdf) ISSN 1798-0062 (pdf) Cover picture: Satu Wedenoja (Monterey, CA, USA on 7 November 2007) http://www.thl.fi/julkaisut http://ethesis.helsinki.fi/ Helsinki University Print Helsinki, Finland 2010 Supervisors Academician Leena Peltonen-Palotie, MD, PhD Professor, Research Director Institute for Molecular Medicine Finland FIMM Nordic EMBL Partnership for Molecular Medicine National Institute for Health and Welfare and University of Helsinki and Department
  • Genome-Wide Association Meta-Analysis for Early Age-Related Macular Degeneration Highlights Novel Loci and Insights for Advanced Disease Thomas W

    Genome-Wide Association Meta-Analysis for Early Age-Related Macular Degeneration Highlights Novel Loci and Insights for Advanced Disease Thomas W

    Winkler et al. BMC Medical Genomics (2020) 13:120 https://doi.org/10.1186/s12920-020-00760-7 RESEARCH ARTICLE Open Access Genome-wide association meta-analysis for early age-related macular degeneration highlights novel loci and insights for advanced disease Thomas W. Winkler1*† , Felix Grassmann2,3,4†, Caroline Brandl1,2,5, Christina Kiel2, Felix Günther1,6, Tobias Strunz2, Lorraine Weidner1, Martina E. Zimmermann1, Christina A. Korb7, Alicia Poplawski8, Alexander K. Schuster7, Martina Müller-Nurasyid8,9,10,11, Annette Peters12,13, Franziska G. Rauscher14,15, Tobias Elze14,16, Katrin Horn14,15, Markus Scholz14,15, Marisa Cañadas-Garre17, Amy Jayne McKnight17, Nicola Quinn17, Ruth E. Hogg17, Helmut Küchenhoff6, Iris M. Heid1†, Klaus J. Stark1† and Bernhard H. F. Weber2,18† Abstract Background: Advanced age-related macular degeneration (AMD) is a leading cause of blindness. While around half of the genetic contribution to advanced AMD has been uncovered, little is known about the genetic architecture of early AMD. Methods: To identify genetic factors for early AMD, we conducted a genome-wide association study (GWAS) meta-analysis (14,034 cases, 91,214 controls, 11 sources of data including the International AMD Genomics Consortium, IAMDGC, and UK Biobank, UKBB). We ascertained early AMD via color fundus photographs by manual grading for 10 sources and via an automated machine learning approach for > 170,000 photographs from UKBB. We searched for early AMD loci via GWAS and via a candidate approach based on 14 previously suggested early AMD variants. (Continued on next page) * Correspondence: [email protected] †Thomas W Winkler and Felix Grassmann contributed equally †Iris M Heid, Klaus J Stark and Bernhard HF Weber jointly supervised this work 1Department of Genetic Epidemiology, University of Regensburg, Regensburg, Germany Full list of author information is available at the end of the article © The Author(s).
  • Potential Impact of Mir-137 and Its Targets in Schizophrenia

    Potential Impact of Mir-137 and Its Targets in Schizophrenia

    Georgia State University ScholarWorks @ Georgia State University Psychology Faculty Publications Department of Psychology 4-2013 Potential Impact of miR-137 and Its Targets in Schizophrenia Carrie Wright University of New Mexico, [email protected] Jessica Turner Georgia State University, [email protected] Vince D. Calhoun University of New Mexico, [email protected] Nora I. Perrone-Bizzozero University of New Mexico, [email protected] Follow this and additional works at: https://scholarworks.gsu.edu/psych_facpub Part of the Psychology Commons Recommended Citation Wright C, Turner JA, Calhoun VD and Perrone-Bizzozero N (2013) Potential impact of miR-137 and its tar- gets in schizophrenia. Front. Genet. 4:58. doi: http://dx.doi.org/10.3389/fgene.2013.00058 This Article is brought to you for free and open access by the Department of Psychology at ScholarWorks @ Georgia State University. It has been accepted for inclusion in Psychology Faculty Publications by an authorized administrator of ScholarWorks @ Georgia State University. For more information, please contact [email protected]. HYPOTHESIS AND THEORY ARTICLE published: 26 April 2013 doi: 10.3389/fgene.2013.00058 Potential impact of miR-137 and its targets in schizophrenia Carrie Wright 1, Jessica A.Turner 2,3*,Vince D. Calhoun2,3 and Nora Perrone-Bizzozero1* 1 Department of Neurosciences, Health Sciences Center, University of New Mexico, Albuquerque, NM, USA 2 The Mind Research Network, Albuquerque, NM, USA 3 Psychology Department, University of New Mexico, Albuquerque, NM, USA Edited by: The significant impact of microRNAs (miRNAs) on disease pathology is becoming increas- Francis J. McMahon, National ingly evident.These small non-coding RNAs have the ability to post-transcriptionally silence Institute of Mental Health, USA the expression of thousands of genes.